Research
Altimmune (ALT) Stock Analysis & Research
- Latest rating
- Sell
- Latest report
- Aug 26, 2026
- Reports
- 1
- Sector
- Healthcare
The Scorecard: 1 Month Update: ALT Sell — Correct so far
Revisiting our Sell call on ALT: entry $3.15, latest $3.06, -2.9%.
Altimmune Stock Analysis: Buy or Sell? Valuation, Cash Burn & Phase 3
Altimmune (ALT) is rated Sell as the stock already prices in Phase 3 success while the business remains pre-revenue. Despite $326.3 million in cash and…
Most Popular Research
EOSEHOLDJun 22, 2026Eos Energy Enterprises Stock Analysis: EOSE Cash Burn, Revenue Growth & Financing RiskEos Energy Enterprises (EOSE) earns a Sell rating as rapid Q1 revenue growth is offset by persistent cash…SOUNSELLJun 14, 2026SoundHound AI Stock Analysis: Buy or Sell? Margin, Cash Burn & ValuationSoundHound AI (SOUN) carries a sell rating because strong revenue growth has not yet translated into self-funding economics.…AMKRSELLJul 27, 2026Amkor Technology Stock Analysis: AMKR Valuation, FCF & RisksAmkor Technology (AMKR) is rated Sell as valuation remains rich while free cash flow is still negative. Customer…CASYJun 22, 2026USDW Stock: Made in USA 10-K Analysis & Growth ThesisMade IN USA (USDW)'s Risk Factors section changed the most among 14 companies that filed 10-Ks on 22…ALTSELLAug 26, 2026Altimmune Stock Analysis: Buy or Sell? Valuation, Cash Burn & Phase 3Altimmune (ALT) is rated Sell as the stock already prices in Phase 3 success while the business remains…QXOHOLDJun 18, 2026QXO Stock Analysis: Valuation, Margins, Free Cash Flow & LeverageQXO, Inc. (QXO) is rated Hold as its valuation already prices in a recovery that has yet to…